| Bioactivity | LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of lysine specific demethylase 1 (LSD1). LSD1-IN-23 has LSD1 inhibitory activity with an IC50 value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB)[1]. |
| Invitro | LSD1-IN-23 (Compound 48) (0-100 μM) 具有有效的 LSD1 抑制活性，IC50 值为 0.58 μM[1]。 LSD1-IN-23 (0.005, 0.037, 0.111, 0.333 μM; 72 h) 显著增加 NB 细胞的整体 H3K4Me2[1]。 LSD1-IN-23 (0.1 μM; 24 h) 与 Bortezomib 联合处理对 NB 细胞有协同作用[1]。 Cell Viability Assay[1] Cell Line: |
| Name | LSD1-IN-23 |
| Formula | C19H13BrClN5O2S |
| Molar Mass | 490.76 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Catherine M Mills, et al. Synthesis and evaluation of small molecule inhibitors of LSD1 for use against MYCN-expressing neuroblastoma. Eur J Med Chem. 2022 Dec 15;244:114818. |